Ethics approval and consent to participate
Cancer
DEL, CANCER
The study was approved by the ethics committee at every participating institution [Melbourne Health Human Research Ethics Committee Parkville, Australia; University Health Network Research Ethics Board, Toronto, Canada; Comite Etico De Investigacion Clinica con medicamentos (CEIm) CEIC del Hospital Universitari Vall d’Hebron, Secretaria del CEIC. Institut Recerca HUVH, Barcelona Spain; Office of Science and Research Institutional Review, New York, NY, USA; New York University School of Medicine IRB, New York, NY, USA; Advarra, Columbia, MD, USA; University of Southern California (USC) Institutional Review Board, Los Angeles, CA, USA; University of Utah Institutional Review Board Research Administration, Salt Lake City, UT, USA; Dana-Farber Cancer Institute Institutional Review Board 450, Boston, MA, USA; Western Institutional Review Board (WIRB), Puyallup, WA, USA; University of Southern California (USC) Institutional Review Board 1640, Los Angeles, CA, USA. The study was conducted according to the recommendations of Good Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent to participate in the study.